Claudin 6 Assay Portfolio Service
With unrivaled expertise and experience in immune-oncology discovery and development, Creative Biolabs is confident in providing an integrated solution for Claudin 6 assay services to best suit your program requirements.
Tumor Target Claudin 6
Claudin 6, a 23 kDa protein, is an important component of the CLDN family and serves a key role in the functions of tight junctions. Claudin 6 shares the common structure of Claudin proteins, consisting of four transmembrane domains, two extracellular loops (ECL1, ECL2), and the intracellular NH2, COOH ends. Claudin 6 can bind with signal proteins and cytoskeletal proteins, inducing epithelial cell junction formation and polarity, regulating the cell proliferation, differentiation and apoptosis of the epithelial cell.
Fig.1 Structural diagram of tight connection. (Du, 2021)
Claudin 6-Targeted Therapies
Claudins are involved in a variety of epithelial-derived cancers. Claudin 6 has been found to be an oncogenic gene in most malignant tumors and may be involved in tumor formation or tumor development. As Claudin 6 is widely expressed in various tumors but rarely expressed in healthy adult tissues, it is used as a promising target for a variety of therapeutic strategies, such as antibodies, ADCs, antibody-drug radionuclide-targeted drugs and CAR-T therapies.
Fig.2 Expression level of Claudin 6 gene in tumors and normal tissues. (Zhang, 2021)
Our Claudin 6 Assay Portfolio Services
Equipped with state-of-the-art facilities, Creative Biolabs has robustly developed tumor marker assay platforms and provides high-quality Claudin 6 assay portfolio services to help our clients meet their program needs.
Features of Our Service
-
Comprehensive Assay Portfolio
A range of related studies from initial basic research to later preclinical trials.
Tumor marker functional assays are MOA-reflective, monitoring target signaling and testing of small molecule or biologic drugs.
Highly reproducible assays for potency for immunotherapy drug discovery and development.
If there is any query, please contact us for more details.
References
-
Du, H.; et al. Claudin 6: Therapeutic prospects for tumors, and mechanisms of expression and regulation. Molecular Medicine Reports. 2021, 24(3): 1-9.
-
Zhang, C.; et al. Identification of Claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Frontiers in cell and developmental biology. 2021: 2052.
For Research Use Only | Not For Clinical Use
Download our brochure